Financings

Ambit Biosciences Corp. withdrew its proposed initial public offering.

Anthera Pharmaceuticals Inc. netted $54 million in a public stock offering.

Constellation Pharmaceuticals Inc. raised $15 million in a Series B extension round.

Cyterix Pharmaceuticals Inc. raised $9.2 million in a Series A financing for cancer prodrugs.

Epiomed Therapeutics Inc. raised an undisclosed amount in a Series A financing.

Northwest Biotherapeutics Inc. raised $3 million in equity and set up a $25 million equity facility.

Deals

Affectis Pharmaceuticals AG signed a $407 million preclinical neurology deal with Merck KgaA.

Clovis Oncology Inc. licensed a Phase I/II PARP inhibitor from Pfizer Inc. in a $255 million+ deal.

Emergent BioSolutions Inc. acquired late-stage anticancer antibody zanolimumab from TenX BioPharma Inc.

Halozyme Therapeutics Inc. licensed delivery technology to Intrexon Corp. for $63 million.

Ligand Pharmaceuticals Inc. licensed an I.V. formulation of clopidogrel to The Medicines Co.

Seattle Genetics Inc. optioned a second antibody-drug conjugate from Astellas Pharma Inc. affiliate Agensys Inc.

Somaxon Pharmaceuticals Inc. signed a $134 million ex-U.S. deal for Silenor (doxepin) with Paladin Labs Inc.

. . . And More

Check out BioWorld Today for coverage of the 47th annual meeting of the American Society for Clinical Oncology, including the latest on targeted therapies, melanoma drugs vemurafenib and ipilimumab, myelofibrosis drugs ruxolitinib and CYT387, cabozantinib and much more.

4SC AG's vidofludimus failed a Phase IIb rheumatoid arthritis trial.

Algeta A/S and Bayer Schering Pharma AG's Phase III Alpharadin trial was halted for strong efficiacy.

Amylin Pharmaceuticals Inc.'s attempt to stop Eli Lilly and Co. from selling Byetta (exenatide) with linagliptin was denied in District Court.

BioSante Pharmaceuticals Inc. said the FDA lifted its clinical hold on cancer vaccine GVAX Prostate.

Intercell AG stopped work on staph vaccine V710 after a Phase II/III failure.

Orexigen Therapeutics Inc. put the brakes on its two obesity drugs pending regulatory guidance.

United Therapeutics Corp.'s Phase III trial of oral treprostinil for pulmonary arterial hypertension met its endpoint.